Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies...
Black Diamond Therapeutics Announces Changes to Board of Directors
December 19, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
December 12, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 09, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing...
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 26, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC BDTX-1535...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical OfficerAdvanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535,...
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 03, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
June 06, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...